Holen Sie sich die Stockscreener-App
1.74
2.08%
-0.0369
Handel nachbörslich:
1.78
0.04
+2.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.7769
Offen:
$1.73
24-Stunden-Volumen:
4.10M
Relative Volume:
1.14
Marktkapitalisierung:
$247.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.2794
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
+7.41%
1M Leistung:
+3.57%
6M Leistung:
+6.75%
1J Leistung:
+58.18%
1-Tages-Spanne:
$1.69
$1.80
1-Wochen-Bereich:
$1.39
$1.8399
52-Wochen-Spanne:
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Vergleichen Sie SLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.74 | 247.85M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
Sellas Life Sciences Progress Sparks Optimism in Market - StocksToTrade
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
SELLAS Life Sciences Gains Momentum with Impressive Phase 2 Data and Financial Strength - timothysykes.com
How institutional buying supports SELLAS Life Sciences Group Inc. stockShare Buyback & High Accuracy Trade Alerts - Newser
How SELLAS Life Sciences Group Inc. (RXK3) stock compares with top peersQuarterly Profit Review & Stock Portfolio Risk Control - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock cheap by valuation metrics2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock a contrarian opportunityBreakout Watch & Weekly Chart Analysis and Guides - Newser
SELLAS Life Sciences Group Inc RXK3 Stock Analysis and ForecastStock Split Announcements & Technical + Fundamental = Smarter Investing - earlytimes.in
[EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing - Stock Titan
SELLAS Advances AML Pipeline With GPS And SLS009 - RTTNews
Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock - MarketBeat
Katherine Kalin Increases Stake in SELLAS Life Sciences Group Inc - GuruFocus
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares By Investing.com - Investing.com Nigeria
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares - Investing.com
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity - Stock Titan
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsWeekly Gains Report & Precise Swing Trade Alerts - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivals2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of rebound - newser.com
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - MarketBeat
How risky is SELLAS Life Sciences Group Inc. stock nowPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdown2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
SELLAS Life Sciences Group Inc. stock prediction for this weekWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
Why millennials buy SELLAS Life Sciences Group Inc. (RXK3) stock2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastWeekly Trade Analysis & Verified Trade Idea Suggestions - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulationWeekly Trend Report & Entry and Exit Point Strategies - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
Should you wait for a breakout in SELLAS Life Sciences Group Inc.Earnings Recap Report & Smart Money Movement Tracker - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 20252025 Dividend Review & Long-Term Growth Portfolio Plans - newser.com
Using economic indicators to assess SELLAS Life Sciences Group Inc. potentialPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Does SELLAS Life Sciences Group Inc. fit your quant trading modelEarnings Risk Report & AI Enhanced Trading Alerts - newser.com
SELLAS Life Sciences Group Inc. stock outlook for YEARJuly 2025 Reactions & Consistent Return Strategy Ideas - newser.com
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sellas Life Sciences Group Inc-Aktie (SLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VAN NOSTRAND ROBERT L | Director |
Jun 12 '25 |
Buy |
1.48 |
10,000 |
14,800 |
20,400 |
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):